"Personalizing" therapy for non-small cell lung cancer.

The sequencing of the human genome has lead to an even greater understanding of the genetic basis of numerous diseases. During the past several years, genetic approaches to a number of solid organ malignancies, including non-small cell lung cancer, have lead us to an increased understanding of the disrupted genetic pathways involved in tumor initiation and progression. Two recent articles are reviewed that highlight the broad potential for successful targeted therapy in thoracic malignancies.